Dutch Biotech Pharming Wins First EU Approval for Rare Disease Treatment

2026-05-23 bio

Leiden, Saturday, 23 May 2026.
Pharming Group becomes the first company to receive European Union approval for treating APDS, a rare immune system disorder affecting quality of life significantly. The Leiden-based biotech will launch in Germany during third quarter 2026, expanding access across all twenty-seven EU member states plus three additional countries.

Breakthrough Medicine for Rare Immune Disease

This development represents a significant advance in medicine, specifically in the treatment of rare immune system disorders. Pharming Group, a Leiden-based biotechnology company, received approval from the European Commission on Friday, May 22, 2026, for its medicine Joenja (leniolisib) [1][2][3]. The drug addresses Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), a rare primary immunodeficiency that causes lifelong, severe impacts on patients and their families [3][4]. APDS significantly compromises quality of life and creates an urgent need for targeted treatment options, according to Leverne Marsh, Pharming’s Chief Commercial Officer [1]. Joenja represents the first specifically approved therapy in Europe for treating this devastating condition [1][2][3].

How the Innovation Works

Joenja functions as an oral inhibitor that directly targets the underlying disease mechanisms of APDS [3][4]. The medicine works by addressing immune dysregulation and immunodeficiency at their source, providing patients with a targeted therapeutic approach rather than merely managing symptoms [GPT]. Professor Ulrich Baumann from Medizinische Hochschule Hannover emphasized that available clinical data consistently showed significant improvement in key parameters of immune dysregulation among APDS patients [1][3]. The drug’s precision targeting of the root cause represents a particularly notable aspect of its therapeutic mechanism [1]. Clinical evidence demonstrates that leniolisib directly addresses the PI3K delta pathway dysfunction that characterizes APDS [GPT].

Global Expansion Strategy and Market Timeline

The European approval follows a successful international rollout strategy that began in 2023. Pharming initially secured approval for Joenja in the United States in 2023, subsequently obtaining market authorizations in the United Kingdom, Japan, Australia, and Israel [1][2]. The company expects to launch the medicine first in Germany during the third quarter of 2026, with additional European markets following after completion of national reimbursement negotiations [2][3][4]. The European Commission’s approval grants marketing rights across all 27 EU member states, plus Norway, Iceland, and Liechtenstein [1][2][3]. This broad geographic coverage provides Pharming with access to a substantial patient population across Europe who previously lacked targeted treatment options for APDS.

Clinical Evidence and Company Background

The European approval rests on robust clinical evidence from a multinational, triple-blinded, placebo-controlled, randomized phase II/III clinical trial involving 31 patients aged 12 years and older [2][3][4]. The study demonstrated statistically significant improvements in immune dysregulation and immunodeficiency parameters [2][3]. Additional supporting data came from a long-term, open-label extension study with 37 patients who received leniolisib for a median of three years [2][3]. Pharming Group, founded in 1988, gained recognition in the 1990s through its genetically modified bull Herman and currently markets Ruconest, a treatment derived from rabbit milk for hereditary angioedema [1]. The Leiden-based company trades on Euronext Amsterdam under the ticker PHARM and on Nasdaq as PHAR [8]. This second therapeutic medicine approval strengthens Pharming’s position as a significant player in the rare disease treatment market and reinforces the Netherlands’ reputation as a major European life sciences hub.

Bronnen

pharmaceutical innovation biotechnology approval